Display options
Cite
Plummer P. Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training. Int J MS Care. 2016;18(3):105-15doi: 10.7224/1537-2073.2014-114.
Plummer, P. (2016). Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training. International journal of MS care, 18(3), 105-15. https://doi.org/10.7224/1537-2073.2014-114
Plummer, Prudence. "Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training." International journal of MS care vol. 18,3 (2016): 105-15. doi: https://doi.org/10.7224/1537-2073.2014-114
Plummer P. Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training. Int J MS Care. 2016 May-Jun;18(3):105-15. doi: 10.7224/1537-2073.2014-114. PMID: 27252597; PMCID: PMC4886996.
Copy Download .nbib Format: NLM
Share it on

Int J MS Care. 2016 May-Jun;18(3):105-15. doi: 10.7224/1537-2073.2014-114.

Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training.

International journal of MS care

Prudence Plummer

Affiliations

  1. Division of Physical Therapy, Department of Allied Health Sciences, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

PMID: 27252597 PMCID: PMC4886996 DOI: 10.7224/1537-2073.2014-114

Abstract

BACKGROUND: Research has not yet compared the treatment effects of dalfampridine with traditional rehabilitation of gait impairments in multiple sclerosis (MS). The purpose of this review was to critically appraise the evidence for dalfampridine and gait training for increasing gait speed in people with MS.

METHODS: A systematic search of the research literature was conducted. Consideration was given to only randomized controlled trials (RCTs), systematic reviews, and meta-analyses. For selection of gait training studies, only studies involving task-specific gait training interventions and measuring treatment effects on gait speed were considered.

RESULTS: Treatment effects on gait speed were extracted from four studies examining the efficacy of dalfampridine and six gait training RCTs. Overall mean increase in gait speed with dalfampridine was 0.07 m/s (95% confidence interval [CI], 0.04-0.09 m/s) compared to 0.06 m/s (95% CI, 0.02-0.10 m/s) for gait training. Among dalfampridine responders (38% of participants in RCTs), the mean increase in gait speed was 0.16 m/s (95% CI, 0.13-0.18 m/s). Mean increases for individual gait training interventions ranged from 0.01 to 0.39 m/s; however, CIs were wide due to small sample sizes.

CONCLUSIONS: Current evidence is insufficient to conclude whether dalfampridine or gait training is superior for improving gait speed in people with MS. These findings should be viewed cautiously due to differences in study populations and small sample sizes in gait training studies. Both treatment approaches provide only short-lived improvements. Head-to-head comparison trials and studies combining both treatment modalities are needed.

References

  1. Neurorehabil Neural Repair. 2012 Mar-Apr;26(3):212-21 - PubMed
  2. Mult Scler. 2007 Mar;13(2):224-31 - PubMed
  3. Neurorehabil Neural Repair. 2009 Feb;23(2):108-16 - PubMed
  4. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):531-3 - PubMed
  5. Clin Rehabil. 2009 Sep;23(9):771-81 - PubMed
  6. Mult Scler. 2007 Jan;13(1):113-9 - PubMed
  7. Neurology. 2008 Oct 7;71(15):1130-1 - PubMed
  8. Rehabil Psychol. 2014 Nov;59(4):415-21 - PubMed
  9. J Neurol Phys Ther. 2013 Dec;37(4):187-93 - PubMed
  10. NeuroRehabilitation. 2010;27(2):121-8 - PubMed
  11. J Rehabil Med. 2010 Oct;42(9):866-72 - PubMed
  12. Mult Scler. 2011 Apr;17(4):468-77 - PubMed
  13. Int J MS Care. 2014 Fall;16(3):153-60 - PubMed
  14. Mult Scler. 2008 Mar;14(2):231-6 - PubMed
  15. J Neurol Phys Ther. 2011 Mar;35(1):26-33 - PubMed
  16. Arch Phys Med Rehabil. 2011 Jan;92(1):31-6 - PubMed
  17. Ann Neurol. 2010 Oct;68(4):494-502 - PubMed
  18. Neurorehabil Neural Repair. 2009 Oct;23(8):784-91 - PubMed
  19. Neuromodulation. 2014 Jan;17(1):75-84; discussion 84 - PubMed
  20. Am J Health Syst Pharm. 2011 Nov 15;68(22):2148-54 - PubMed
  21. J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):174-9 - PubMed
  22. J Clin Pharmacol. 2014 Jan;54(1):53-60 - PubMed
  23. J Neurol Phys Ther. 2011 Mar;35(1):2-10 - PubMed
  24. J Aging Phys Act. 2015 Apr;23(2):314-22 - PubMed
  25. Clin Rehabil. 2013 Dec;27(12):1126-36 - PubMed
  26. Clin Rehabil. 1998 Dec;12(6):477-86 - PubMed
  27. Mult Scler. 2009 Apr;15(4):493-504 - PubMed
  28. Mult Scler Int. 2012;2012:240274 - PubMed
  29. Neurology. 2004 Dec 14;63(11):2034-8 - PubMed
  30. Mult Scler. 2011 Nov;17(11):1362-74 - PubMed
  31. Neurology. 1996 Dec;47(6):1457-62 - PubMed
  32. Clin Ther. 2009 Oct;31(10):2206-14 - PubMed
  33. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003980 - PubMed
  34. Mult Scler. 2013 Feb;19(2):209-16 - PubMed
  35. Neurorehabil Neural Repair. 2008 Nov-Dec;22(6):661-71 - PubMed
  36. Neurorehabil Neural Repair. 2013 Jul-Aug;27(6):516-25 - PubMed
  37. Acta Neurol Scand. 1982 Sep;66(3):355-62 - PubMed
  38. Neurology. 2008 Oct 7;71(15):1134-41 - PubMed
  39. Mult Scler. 2012 Jun;18(6):881-90 - PubMed
  40. NeuroRehabilitation. 2013;32(3):655-63 - PubMed
  41. Mult Scler. 2008 Aug;14 (7):988-91 - PubMed
  42. Lancet. 2009 Feb 28;373(9665):732-8 - PubMed
  43. Am J Phys Med Rehabil. 2010 Jun;89(6):446-57 - PubMed
  44. Neurorehabil Neural Repair. 2010 Nov-Dec;24(9):835-42 - PubMed
  45. J Clin Pharmacol. 2010 Feb;50(2):151-9 - PubMed
  46. Clin Rehabil. 2012 Jul;26(7):579-93 - PubMed
  47. Phys Ther. 2007 Dec;87(12 ):1580-602 - PubMed
  48. Pharmacol Ther. 2006 Jul;111(1):224-59 - PubMed
  49. QJM. 2004 Oct;97(10):671-6 - PubMed
  50. Neuropsychiatr Dis Treat. 2011;7:229-39 - PubMed
  51. Mult Scler. 2006 Apr;12(2):235-42 - PubMed
  52. Qual Life Res. 2013 Mar;22(2):253-61 - PubMed
  53. Ann Neurol. 2010 Jul;68(1):A8-9 - PubMed

Publication Types